Catalog for weight loss

Mounjaro (tirzepatide) — dual GLP-1/GIP agonist with up to 22.5% weight loss. Ozempic (semaglutide) — GLP-1 agonist with up to 15% weight loss. Retatrutide — next-generation triple GLP-1/GIP/glucagon agonist. Cagrilintide — amylin analog that enhances GLP-1 agonist effects in combination therapy. Biopatid (UNIKKA PHARMA) claims tirzepatide as active ingredient but has no proprietary RCTs and is not FDA/EMA registered.

Mounjaro — from 8,000 ₴ (program) or from 17,000 ₴ (KwikPen), Ozempic — from 8 800 ₴, Cagrilintide — from 7,000 ₴, Retatrutide — from 15,500 ₴. Biopatid — market price from ~9,000 ₴ (10 mg). Current prices in each product's catalog.

The choice depends on your goals, budget, and individual needs. Mounjaro — maximum effectiveness with evidence base (SURMOUNT-1). Ozempic — proven classic option (FDA/EMA). Retatrutide — next-generation triple agonist. Cagrilintide — for combination therapy. Biopatid claims the same substance as Mounjaro but lacks its own research — consider this when choosing. Take a free test or contact a specialist.

Yes, delivery across all of Ukraine. All medications are delivered in special thermal packaging maintaining the cold chain at 2–8°C. Delivery usually takes 1–3 days.

Mounjaro — UK original by Eli Lilly, Ozempic — by Novo Nordisk. Biopatid is manufactured by UNIKKA PHARMA (Brazil) — it's not an original Eli Lilly product, but a branded analog without its own clinical trials. DOZA clearly labels the status of each product.